PRNB Insider Trading Activity and SEC Form 4 Filings
PRNB insider trading summary
No open-market insider purchases or sales of Principia Biopharma Inc. (PRNB) have been reported on SEC Form 4 in the past 12 months.
Latest PRNB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 18, 2020 | Roy C. Hardiman | Chief Business Officer | Sell | $500K (5,000 @ $99.98) |
| Aug 18, 2020 | Christopher Y Chai | Chief Financial Officer | Sell | $745K (7,500 @ $99.37) |
| Aug 18, 2020 | Dolca Thomas | Chief Medical Officer | Sell | $1.5M (15,000 @ $100.00) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $61K (700 @ $86.92) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $9K (100 @ $93.34) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $101K (1,108 @ $90.99) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $63K (700 @ $89.68) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $74K (858 @ $86.11) |
| Aug 10, 2020 | David M Goldstein | Chief Scientific Officer | Sell | $224K (2,534 @ $88.40) |
| Jul 15, 2020 | Dolca Thomas | Chief Medical Officer | Sell | $1.2M (15,000 @ $80.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.